- Home
- EAF vs AURA Comparison
EAF vs AURA Comparison
Compare EAF & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAF | AURA |
|---|---|---|
| Founded | 1886 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.0M | 396.8M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EAF | AURA |
|---|---|---|
| Price | $15.93 | $5.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $14.25 | ★ $20.20 |
| AVG Volume (30 Days) | ★ 184.7K | 163.5K |
| Earning Date | 02-06-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $521,894,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $4.35 |
| 52 Week High | $20.32 | $8.60 |
Technical Indicators
Market Signals| Indicator | EAF | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 36.81 |
| Support Level | $13.91 | $5.73 |
| Resistance Level | $17.09 | $6.15 |
| Average True Range (ATR) | 1.09 | 0.32 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 51.94 | 0.00 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.